2025-01-12 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Investment Report

**1. Performance Comparison and Outperformance:**

Intuitive Surgical Inc. (ISRG) is a company that develops, manufactures, and sells surgical robots.  The cumulative return of ISRG is 299.30%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 112.20%.  The difference in cumulative returns is approximately 187.1 percentage points. This places ISRG at the 99.3rd percentile of its historical relative performance against the S&P 500 based on the provided data.  The provided alpha values are consistently 0, which implies the model is struggling to differentiate performance above the benchmark after accounting for beta.  This is potentially due to data limitations, model simplification or a lack of significant factor-adjusted alpha.

**2. Recent Price Movement:**

* **Closing Price:** $547.47
* **5-Day Moving Average:** $540.21
* **20-Day Moving Average:** $535.09
* **60-Day Moving Average:** $528.80

The price is above all three moving averages, suggesting a short-term uptrend.

**3. Technical Indicators and Expected Return:**

* **RSI:** 62.99 (Neither overbought nor oversold)
* **PPO:** 0.22 (Positive, suggesting bullish momentum)
* **20-Day Relative Strength Change:** +9.4% (Indicates a recent surge in relative strength)
* **Expected Return (2+ years):** 16.9% (Significantly above the implied S&P 500 return)

The current price of $547.47 is not significantly unusual relative to its recent trend, given its movement above the moving averages. There is no evidence of a drastic price jump or drop.  The high expected return suggests substantial outperformance over the long term relative to the S&P 500, but the actual results may vary.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-10-18 | $1.59  | $2.04B      |
| 2024-07-19 | $1.48  | $2.01B      |
| 2024-04-19 | $1.54  | $1.89B      |
| 2023-10-20 | $1.18  | $1.74B      |
| 2024-10-18 | $1.18  | $1.74B      | *(Duplicate entry, likely a data error)*


Earnings have generally increased quarter-over-quarter, indicating positive growth. The duplicated entry needs clarification.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-09-30  | $2.04B      | 67.41%        |
| 2024-06-30  | $2.01B      | 68.30%        |
| 2024-03-31  | $1.89B      | 65.87%        |
| 2023-12-31  | $1.93B      | 66.24%        |
| 2023-09-30  | $1.74B      | 66.94%        |

Revenue is generally increasing, and profit margins remain consistently high, suggesting strong financial health.

**Capital and Profitability:**

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-09-30  | $15.58B     | 3.63%         |
| 2024-06-30  | $14.71B     | 3.58%         |
| 2024-03-31  | $13.96B     | 3.90%         |
| 2023-12-31  | $13.31B     | 4.56%         |
| 2023-09-30  | $12.54B     | 3.32%         |

Equity is growing steadily. ROE fluctuates but remains positive, indicating profitable use of capital.


**7. Overall Analysis:**

ISRG demonstrates a strong track record of outperformance relative to the S&P 500, with consistently high revenue and profit margins.  Technical indicators suggest positive momentum.  The high projected long-term return, coupled with positive financial performance, makes ISRG a potentially attractive investment, particularly for long-term investors. However, it is crucial to acknowledge the limitations of the provided alpha data and conduct further independent due diligence before making any investment decisions.  The duplicated earnings data point warrants further investigation to ensure data accuracy.

**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on thorough research and consideration of individual risk tolerance.
